Showing results (81-90 of 897) with videos related to
Sort By:
Pageof 90
Blood Advances|August 31, 2021
Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapseBachar Samra, Joseph D Khoury, Kiyomi Morita, et al.British Journal of Haematology|May 9, 2024
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous diseaseWei-Ying Jen, Hagop Kantarjian, Tapan M Kadia, et al.Leukemia & Lymphoma|August 9, 2025
Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phaseOmer Karrar, Hagop Kantarjian, Fadi G Haddad, et al.Clinical Lymphoma, Myeloma & Leukemia|July 2, 2026
Results of Third-Line Therapy in Philadelphia Chromosome-Positive Adult Acute Lymphoblastic LeukemiaWei-Ying Jen, Elias Jabbour, Eitan Kugler, et al.American Journal of Hematology|November 6, 2018
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American expertsNicholas J Short, Elias Jabbour, Maher Albitar, et al.Hematology/Oncology Clinics of North America|September 23, 2006
Monoclonal antibody therapy for hairy cell leukemiaDeborah A Thomas, Farhad Ravandi, Hagop KantarjianHaematologica|May 4, 2023
Maintenance therapy in acute myeloid leukemia: advances and controversiesJayastu Senapati, Tapan M Kadia, Farhad RavandiLeukemia & Lymphoma|March 29, 2011
The microenvironment in hairy cell leukemia: pathways and potential therapeutic targetsJan A Burger, Mariela Sivina, Farhad RavandiJournal of Hematology & Oncology|May 14, 2025
Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomabNicholas J Short, Hagop Kantarjian, Ken Furudate, et al.Cancer|February 21, 2025
Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaEitan Kugler, Hagop Kantarjian, Elias Jabbour, et al.Pageof 90